Dr. Hong joined RiverVest in 2016 and focuses on both biopharmaceutical and medical device opportunities, contributing to the formation, development, and strategic direction of RiverVest portfolio companies. Currently, she serves as a member of the Board of Directors at Scout Bio, Inc., Bluejay Therapeutics, and Biolinq, Inc. Dr. Hong formerly was a member of the Board of Directors at Xilio Therapeutics (NASDAQ: XLO).
Previously, Dr. Hong was a principal with BioMed Ventures, where she originated and managed successful investments in therapeutics, diagnostics, and medical devices. Prior to BioMed, she was an investment professional at Forward Ventures and served as an advisor to biotech and pharmaceutical companies entering new areas of research. She started her career as a scientist at Phenomix, a venture-backed discovery biotech company in San Diego. She trained in the areas of immunology and oncology, earning a B.S. with honors in Biology from the California Institute of Technology and a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley. She conducted postdoctoral training at the University of California, San Francisco, as a fellow of the Leukemia & Lymphoma Society.